Davis Ian C, Zajac Allan J, Nolte Kurt B, Botten Jason, Hjelle Brian, Matalon Sadis
Department of Anesthesiology, University of Alabama at Birmingham, 35294, USA.
J Virol. 2002 Aug;76(16):8347-59. doi: 10.1128/jvi.76.16.8347-8359.2002.
Hantavirus cardiopulmonary syndrome (HCPS) is a life-threatening respiratory disease characterized by profound pulmonary edema and myocardial depression. Most cases of HCPS in North America are caused by Sin Nombre virus (SNV), which is carried asymptomatically by deer mice (Peromyscus maniculatus). The underlying pathophysiology of HCPS is poorly understood. We hypothesized that pathogenic SNV infection results in increased generation of reactive oxygen/nitrogen species (RONS), which contribute to the morbidity and mortality of HCPS. Human disease following infection with SNV or Andes virus was associated with increased nitrotyrosine (NT) adduct formation in the lungs, heart, and plasma and increased expression of inducible nitric oxide synthase (iNOS) in the lungs compared to the results obtained for normal human volunteers. In contrast, NT formation was not increased in the lungs or cardiac tissue from SNV-infected deer mice, even at the time of peak viral antigen expression. In a murine (Mus musculus) model of HCPS (infection of NZB/BLNJ mice with lymphocytic choriomeningitis virus clone 13), HCPS-like disease was associated with elevated expression of iNOS in the lungs and NT formation in plasma, cardiac tissue, and the lungs. In this model, intraperitoneal injection of 1400W, a specific iNOS inhibitor, every 12 h during infection significantly improved survival without affecting intrapulmonary fluid accumulation or viral replication, suggesting that cardiac damage may instead be the cause of mortality. These data indicate that elevated production of RONS is a feature of pathogenic New World hantavirus infection and that pharmacologic blockade of iNOS activity may be of therapeutic benefit in HCPS cases, possibly by ameliorating the myocardial suppressant effects of RONS.
汉坦病毒心肺综合征(HCPS)是一种危及生命的呼吸系统疾病,其特征为严重肺水肿和心肌抑制。北美地区的大多数HCPS病例由辛诺柏病毒(SNV)引起,该病毒由鹿鼠(白足鼠)无症状携带。HCPS的潜在病理生理学机制尚不清楚。我们推测,致病性SNV感染会导致活性氧/氮物种(RONS)生成增加,这会导致HCPS的发病和死亡。与正常人类志愿者相比,感染SNV或安第斯病毒后的人类疾病与肺、心脏和血浆中硝基酪氨酸(NT)加合物形成增加以及肺中诱导型一氧化氮合酶(iNOS)表达增加有关。相比之下,即使在病毒抗原表达高峰期,SNV感染的鹿鼠的肺或心脏组织中NT形成也没有增加。在HCPS的小鼠(小家鼠)模型(用淋巴细胞性脉络丛脑膜炎病毒克隆13感染NZB/BLNJ小鼠)中,类似HCPS的疾病与肺中iNOS表达升高以及血浆、心脏组织和肺中NT形成有关。在该模型中,感染期间每12小时腹腔注射一次特异性iNOS抑制剂1400W可显著提高生存率,而不影响肺内液体蓄积或病毒复制,这表明心脏损伤可能是死亡原因。这些数据表明,RONS产生增加是致病性新大陆汉坦病毒感染的一个特征,iNOS活性的药物阻断可能对HCPS病例有治疗益处,可能是通过改善RONS的心肌抑制作用。